A vet takes an X-ray. Uploads it to a cloud platform. Gets a read from a board-certified radiologist. Calls the pet owner with a diagnosis and a treatment plan. That sequence just changed hands, and the company that makes the drugs is now the one running the radiology service.
Here's what just happened
Zoetis announced it's acquiring VitalRADS, a veterinary teleradiology platform that provides around-the-clock access to board-certified specialists. VitalRADS reviews digital radiographs, ECGs, CT scans, and MRI scans across more than 25 species, delivering same-day results and two-hour STAT reads. The platform serves more than 1,800 active customers, corporate and independent practices plus universities, and operates mobile ultrasound services in the Greater Houston and Greater Seattle regions, covering over 200 clinics. It also runs an outpatient imaging center in Cypress, Texas, and offers VitalPACS, a cloud-based Picture Archiving and Communication System that integrates directly with medical record systems. The deal is expected to close in the third quarter of 2026. Financial terms weren't disclosed.
Zoetis had already announced a partnership with VitalRADS in August 2025. This acquisition folds the platform into Zoetis' Global Diagnostics portfolio, which includes the Vetscan Imagyst and Vetscan Opticell point-of-care testing platforms. The company calls the combined offering a "Virtual Reference Laboratory", board-certified specialists paired with AI-assisted report generation and quality assurance.
Why this is actually a big deal
When a major animal pharma company owns the diagnostic interpretation layer, it's not just about radiology reads. It's about controlling the moment when a vet says 'your dog needs X', and what that does to the products retailers actually move.
A vet who can access specialist-reviewed diagnostics through an integrated platform may be more likely to move directly to a treatment plan. That's a different path than the one where a customer walks into a pet store looking for a supplement to try first. Zoetis now controls both ends of that loop: the diagnostic platform that identifies the condition, and the pharmaceutical products prescribed to treat it. Jamie Brannan, Zoetis' Executive Vice President and Chief Commercial Officer, said the acquisition helps veterinarians "identify conditions faster, inform clinical decision-making, and guide treatment plans." That's good for the pet. It's also a shift in where the retail opportunity sits.
What this means for the shelf
For the store owner: If you've built relationships with local vet practices that send customers your way for supplements or premium food, this is worth watching. When diagnostic services become more integrated into a pharma company's ecosystem, the referral pattern can shift. Your play is to deepen relationships with the independent practices in your area, and to make sure your staff can speak fluently about the difference between a supplement and a pharmaceutical when a customer walks in with questions.
For the buyer: If you stock joint health, digestive support, or other wellness categories where vets sometimes recommend trying a product before running tests, pay attention to how diagnostic access changes in your market. The counter-move is to stock products that complement a diagnosis, not replace it: post-surgical recovery treats, mobility aids, prescription-diet adjacencies. The "try this first" SKU may face headwinds. The "use this alongside treatment" SKU may gain ground.
For the brand/DTC operator: If you're pitching joint or digestive supplements to independents, consider how your positioning holds up when diagnostic access becomes more seamless. Your story is either clinical-grade differentiation ("this is what the vet prescribes after the diagnosis") or lifestyle positioning ("this is what proactive owners use before there's a problem"). Adjust your pitch and your packaging accordingly.
When the pharma company owns the diagnostic moment, the 'try this supplement first' conversation doesn't disappear. It just moves earlier in the pet's life, or later in the treatment plan.
How we're thinking about it
This is vertical integration in the least obvious place. Zoetis isn't buying a retailer or a distributor. It's buying the interpretive layer that sits between the symptom and the prescription. That's a longer play than most M&A in this industry, and it's aimed at a different part of the value chain.
The retail impact is worth watching. When diagnostics become more accessible through integrated platforms, the timing and context of a customer's purchase can shift. The "try this for a while" purchase may become a "use this for long-term support" purchase. That's a different margin conversation, a different merchandising strategy, and a different relationship with the vet down the street.
We're also watching the independent-practice angle. VitalRADS serves corporate and independent clinics, but if the diagnostic stack gets tighter and more integrated, independent practices that can't access these platforms may lose a competitive edge, and those practices are often retailers' strongest referral partners for food and supplement crossover.
If this is the kind of operator-level read you want every week, subscribe to PetRetailNews.
What to do about it
-
If you rely on vet referrals for supplement sales... map which practices in your area are independent versus corporate, and which use teleradiology platforms. The independents without integrated diagnostic access may be your strongest referral partners. Deepen those relationships.
-
If you're a category buyer watching joint health or digestive SKUs... track your turn data over the coming quarters. If you see shifts that don't align with pricing or promo, consider whether diagnostic access in your market is changing the purchase path. Start testing post-diagnosis positioning: "recommended alongside treatment" rather than "try this first."
-
If you're a brand trying to win independent distribution... rewrite your sell sheet. Lead with clinical differentiation (if you have it) or lifestyle prevention (if you don't). Make sure your positioning works whether the customer is coming in before or after a vet visit.
-
If you run a store near a corporate vet chain... stock the adjacencies: post-surgical recovery treats, mobility aids, calming products for the ride home from the imaging center. The diagnostic visit is still a retail trigger, it's just a different trigger than it used to be.
-
If you're watching M&A in vet services... this is another data point. When pharma companies acquire diagnostic platforms, the care pathway changes. Your hedge is to become the trusted voice on nutrition and wellness before the vet visit happens, not after.
The Bottom Line
When the company that makes the drugs also runs the radiology service, the "try this supplement first" moment doesn't disappear, it just moves. Retailers who see that shift coming can reposition before the data tells the story.